{"id":"https://openalex.org/W4410998636","doi":"https://doi.org/10.1016/j.jcf.2025.03.602","title":"EPS2.05LONGITUDE-Non-F: an observational study evaluating outcomes of ELX/TEZ/IVA in people with cystic fibrosis aged \u22656 years with non-F508del CFTR variants using data from the UK CF Registry","display_name":"EPS2.05LONGITUDE-Non-F: an observational study evaluating outcomes of ELX/TEZ/IVA in people with cystic fibrosis aged \u22656 years with non-F508del CFTR variants using data from the UK CF Registry","publication_year":2025,"publication_date":"2025-06-01","ids":{"openalex":"https://openalex.org/W4410998636","doi":"https://doi.org/10.1016/j.jcf.2025.03.602"},"language":"en","primary_location":{"id":"doi:10.1016/j.jcf.2025.03.602","doi":"https://doi.org/10.1016/j.jcf.2025.03.602","is_oa":false,"landing_page_url":"https://doi.org/10.1016/j.jcf.2025.03.602","pdf_url":null,"source":{"id":"https://openalex.org/S147774598","display_name":"Journal of Cystic Fibrosis","issn_l":"1569-1993","issn":["1569-1993","1873-5010"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Cystic Fibrosis","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5110962612","display_name":"Carl A. Baxter","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I61970326","display_name":"Vertex Pharmaceuticals (United States)","ror":"https://ror.org/00anb1726","country_code":"US","type":"company","lineage":["https://openalex.org/I61970326"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"C.A. Baxter","raw_affiliation_strings":["Vertex Pharmaceuticals Incorporated, Boston, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Vertex Pharmaceuticals Incorporated, Boston, United States","institution_ids":["https://openalex.org/I61970326"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5082181496","display_name":"Jamie M Duckers","orcid":"https://orcid.org/0000-0003-3004-279X","observed_orcids":["https://orcid.org/0000-0003-3004-279X"]},"institutions":[{"id":"https://openalex.org/I4210146878","display_name":"University Hospital Llandough","ror":"https://ror.org/05fcrn131","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I1299209451","https://openalex.org/I4210144625","https://openalex.org/I4210146878"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"J. Duckers","raw_affiliation_strings":["University Hospital Llandough, Penarth, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University Hospital Llandough, Penarth, United Kingdom","institution_ids":["https://openalex.org/I4210146878"]}]},{"author_position":"middle","author":{"id":null,"display_name":"E. Muller","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I61970326","display_name":"Vertex Pharmaceuticals (United States)","ror":"https://ror.org/00anb1726","country_code":"US","type":"company","lineage":["https://openalex.org/I61970326"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"E. Muller","raw_affiliation_strings":["Vertex Pharmaceuticals Incorporated, Boston, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Vertex Pharmaceuticals Incorporated, Boston, United States","institution_ids":["https://openalex.org/I61970326"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5117817175","display_name":"J. Milovic","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I61970326","display_name":"Vertex Pharmaceuticals (United States)","ror":"https://ror.org/00anb1726","country_code":"US","type":"company","lineage":["https://openalex.org/I61970326"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"J. Milovic","raw_affiliation_strings":["Vertex Pharmaceuticals Incorporated, Boston, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Vertex Pharmaceuticals Incorporated, Boston, United States","institution_ids":["https://openalex.org/I61970326"]}]},{"author_position":"middle","author":{"id":null,"display_name":"F. Adams","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2800216163","display_name":"Cystic Fibrosis Trust","ror":"https://ror.org/03xeae684","country_code":"GB","type":"nonprofit","lineage":["https://openalex.org/I2800216163"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"F. Adams","raw_affiliation_strings":["Cystic Fibrosis Trust, London, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cystic Fibrosis Trust, London, United Kingdom","institution_ids":["https://openalex.org/I2800216163"]}]},{"author_position":"middle","author":{"id":null,"display_name":"S.L. Clarke","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2800216163","display_name":"Cystic Fibrosis Trust","ror":"https://ror.org/03xeae684","country_code":"GB","type":"nonprofit","lineage":["https://openalex.org/I2800216163"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"S.L. Clarke","raw_affiliation_strings":["Cystic Fibrosis Trust, London, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cystic Fibrosis Trust, London, United Kingdom","institution_ids":["https://openalex.org/I2800216163"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072106301","display_name":"Susan C. Charman","orcid":"https://orcid.org/0000-0002-1887-9311","observed_orcids":["https://orcid.org/0000-0002-1887-9311"]},"institutions":[{"id":"https://openalex.org/I2800216163","display_name":"Cystic Fibrosis Trust","ror":"https://ror.org/03xeae684","country_code":"GB","type":"nonprofit","lineage":["https://openalex.org/I2800216163"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"S.C. Charman","raw_affiliation_strings":["Cystic Fibrosis Trust, London, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cystic Fibrosis Trust, London, United Kingdom","institution_ids":["https://openalex.org/I2800216163"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5044501689","display_name":"Gabriela Vega-Hernandez","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I61970326","display_name":"Vertex Pharmaceuticals (United States)","ror":"https://ror.org/00anb1726","country_code":"US","type":"company","lineage":["https://openalex.org/I61970326"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"G. Vega-Hernandez","raw_affiliation_strings":["Vertex Pharmaceuticals Incorporated, Boston, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Vertex Pharmaceuticals Incorporated, Boston, United States","institution_ids":["https://openalex.org/I61970326"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":4370,"currency":"USD","value_usd":4370},"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.16903718,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"24","issue":null,"first_page":"S43","last_page":"S43"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10665","display_name":"Cystic Fibrosis Research Advances","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10665","display_name":"Cystic Fibrosis Research Advances","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11651","display_name":"Inhalation and Respiratory Drug Delivery","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11189","display_name":"Transplantation: Methods and Outcomes","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2746","display_name":"Surgery"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/elexacaftor-tezacaftor-ivacaftor","display_name":"elexacaftor/tezacaftor/ivacaftor","score":0.9629999995231628},{"id":"https://openalex.org/keywords/cftr-modulator-therapy","display_name":"CFTR modulator therapy","score":0.8700000047683716},{"id":"https://openalex.org/keywords/cftr-mutations","display_name":"CFTR mutations","score":0.5680000185966492},{"id":"https://openalex.org/keywords/ppfev1","display_name":"ppFEV1","score":0.7170000076293945},{"id":"https://openalex.org/keywords/pulmonary-exacerbations","display_name":"pulmonary exacerbations","score":0.6430000066757202},{"id":"https://openalex.org/keywords/body-mass-index","display_name":"body mass index","score":0.6899999976158142},{"id":"https://openalex.org/keywords/survival","display_name":"survival","score":0.5440000295639038},{"id":"https://openalex.org/keywords/lung-transplantation","display_name":"lung transplantation","score":0.8080000281333923},{"id":"https://openalex.org/keywords/treatment-discontinuation","display_name":"treatment discontinuation","score":0.6919999718666077},{"id":"https://openalex.org/keywords/real-world-outcomes","display_name":"real-world outcomes","score":0.7179999947547913}],"concepts":[{"id":"https://openalex.org/C2776938444","wikidata":"https://www.wikidata.org/wiki/Q178194","display_name":"Cystic fibrosis","level":2,"score":0.9732177257537842},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8900772333145142},{"id":"https://openalex.org/C23131810","wikidata":"https://www.wikidata.org/wiki/Q818574","display_name":"Observational study","level":2,"score":0.7681101560592651},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4654475152492523},{"id":"https://openalex.org/C187212893","wikidata":"https://www.wikidata.org/wiki/Q123028","display_name":"Pediatrics","level":1,"score":0.36536139249801636},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.3295390009880066}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1016/j.jcf.2025.03.602","doi":"https://doi.org/10.1016/j.jcf.2025.03.602","is_oa":false,"landing_page_url":"https://doi.org/10.1016/j.jcf.2025.03.602","pdf_url":null,"source":{"id":"https://openalex.org/S147774598","display_name":"Journal of Cystic Fibrosis","issn_l":"1569-1993","issn":["1569-1993","1873-5010"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Cystic Fibrosis","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"sustainable_development_goals_aurora":[],"study_designs":[{"display_name":"Observational Study","id":"https://openalex.org/study-designs/observational-study"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4410975800","https://openalex.org/W4410390895","https://openalex.org/W7160516781","https://openalex.org/W4353046996","https://openalex.org/W4393204854","https://openalex.org/W4404103506","https://openalex.org/W4416134508","https://openalex.org/W4391388488","https://openalex.org/W4402558775","https://openalex.org/W4416104338"],"abstract_inverted_index":null,"counts_by_year":[],"updated_date":"2026-09-29T14:09:16.559479","created_date":"2025-10-10T00:00:00"}